pemigatinib

{
  "id": "MLC-T-ONC-006472",
  "term": "pemigatinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with certain types of cholangiocarcinoma (bile duct cancer), myeloid cancer, or lymphoid cancer that have certain changes in the structure of the FGFR1 gene or FGFR2 gene. It is also being studied in the treatment of other types of cancer. Pemigatinib blocks a protein called FGFR, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called Pemazyre.",
    "An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Pemigatinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells. FGFR, a family of receptor tyrosine kinases upregulated in many tumor cell types, plays a key role in cellular proliferation, migration, and survival."
  ],
  "synonyms": [
    "Pemazyre",
    "FGFR inhibitor INCB054828"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pemigatinib/"
}